Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences:

Citi's 2025 Biopharma Back to School Conference
Fireside Chat: Tuesday, September 2nd, 2025, at 11:15am ET
Location: Boston, MA

A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.

Baird 2025 Global Healthcare Conference
1x1 Investor Meetings: Tuesday, September 9th, 2025
Location: New York, NY

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.